Atyr Pharma Stock Fundamentals
ATyr Pharma fundamentals help investors to digest information that contributes to ATyr Pharma's financial success or failures. It also enables traders to predict the movement of ATyr Stock. The fundamental analysis module provides a way to measure ATyr Pharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to ATyr Pharma stock.
ATyr |
ATyr Pharma Company Return On Asset Analysis
ATyr Pharma's Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Current ATyr Pharma Return On Asset | -0.29 |
Most of ATyr Pharma's fundamental indicators, such as Return On Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, ATyr Pharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
CompetitionBased on the latest financial disclosure, ATyr Pharma has a Return On Asset of -0.2937. This is 96.64% lower than that of the Biotechnology sector and 98.76% lower than that of the Health Care industry. The return on asset for all United States stocks is 109.79% higher than that of the company.
ATyr Pharma Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining ATyr Pharma's current stock value. Our valuation model uses many indicators to compare ATyr Pharma value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across ATyr Pharma competition to find correlations between indicators driving ATyr Pharma's intrinsic value. More Info.ATyr Pharma is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . Comparative valuation analysis is a catch-all technique that is used if you cannot value ATyr Pharma by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.ATyr Return On Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses ATyr Pharma's direct or indirect competition against its Return On Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of ATyr Pharma could also be used in its relative valuation, which is a method of valuing ATyr Pharma by comparing valuation metrics of similar companies.ATyr Pharma is currently under evaluation in return on asset category among its peers.
ATyr Fundamentals
| Return On Equity | -0.56 | |||
| Return On Asset | -0.29 | |||
| Operating Margin | (70.79) % | |||
| Current Valuation | 55.05 M | |||
| Shares Outstanding | 69.01 M | |||
| Shares Owned By Insiders | 2.61 % | |||
| Shares Owned By Institutions | 61.69 % | |||
| Number Of Shares Shorted | 343.41 K | |||
| Price To Earning | (2.19) X | |||
| Price To Book | 1.30 X | |||
| Price To Sales | 334.89 X | |||
| Revenue | 353 K | |||
| Gross Profit | (32.42 M) | |||
| EBITDA | (52.18 M) | |||
| Net Income | (50.39 M) | |||
| Cash And Equivalents | 88.55 M | |||
| Cash Per Share | 3.09 X | |||
| Total Debt | 15.1 M | |||
| Debt To Equity | 0.01 % | |||
| Current Ratio | 10.08 X | |||
| Book Value Per Share | 1.24 X | |||
| Cash Flow From Operations | (33.22 M) | |||
| Short Ratio | 0.60 X | |||
| Earnings Per Share | (0.88) X | |||
| Target Price | 24.6 | |||
| Number Of Employees | 56 | |||
| Beta | 1.19 | |||
| Market Capitalization | 131.12 M | |||
| Total Asset | 122.07 M | |||
| Retained Earnings | (468.02 M) | |||
| Working Capital | 86.58 M | |||
| Current Asset | 97.95 M | |||
| Current Liabilities | 12.15 M | |||
| Net Asset | 122.07 M |
About ATyr Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze ATyr Pharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of ATyr Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of ATyr Pharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. The company was incorporated in 2005 and is headquartered in San Diego, California. Atyr Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 49 people.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in census. You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.
Other Consideration for investing in ATyr Stock
If you are still planning to invest in ATyr Pharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the ATyr Pharma's history and understand the potential risks before investing.
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas |